AbSci and Sanofi entered into a collaboration to improve the manufacturability for two of Sanofi's biotherapeutics VANCOUVER, Wash., Jan. 9, 2019 /PRNewswire/ AbSci, a global leader in biotherapeutic discovery and manufacturing technologies, today announced a collaboration with Sanofi. Under the terms of the agreement, AbSci will apply its breakthrough E.coli manufacturing platform, SoluProTM, and its novel optimization assay system, to two of Sanofi's biotherapeutic molecules. AbSci's proprietary technology platform is designed with the ability to rapidly achieve optimized, scalable, high-quality, high-titer production of any class of biotherapeutic molecule, including traditionally difficult to manufacture molecules and next-generation scaffolds. The collaboration will take place at AbSci and be funded by Sanofi. "It is exciting to partner with a renowned company like Sanofi," said Sean McClain, CEO of AbSci. "This collaboration illustrates the need for new expression technologies that are capable of producing these next-generation antibody and protein scaffolds. We've shown SoluProTM can uniquely deliver on this industry need." About AbSci AbSci is a global leader in biomanufacturing technologies. Its patented SoluPro™ expression platform rapidly produces complex proteins, ranging from mAbs, Fabs, enzymes, hormones and peptides to the most novel classes of biotherapeutics, at high-titers and high-quality. AbSci's unique approach increases discovery throughput, [...]
About Michael ArmstrongThis author has not yet filled in any details.
So far Michael Armstrong has created 3 blog entries.
Veana Therapeutics is pleased to announce a Phase I Small Business Innovation Research (SBIR) grant award from the NIH National Cancer Institute to conduct proof-of-concept pre-clinical studies of its lead product, VIMO (Veana Immune Modulator) in combination with immune checkpoint inhibitors in triple negative breast cancer. Learn more about Veana here.
By Denise Szott – Contributing writer for Portland Business Journal The Portland company developed a drug to cure malaria that is easy and cheap to manufacture DesignMedix co-founder and Chief Scientific Officer David Peyton and a student carry out research at the DesignMedix Lab in the Portland State Most of us have felt annoyed by the itchy red bump left by a mosquito dining on our blood. But in many parts of the world, the pesky insect’s bite has a far more serious consequence – deadly malaria. With more than 200 million annual cases of malaria globally, scientists for years have been working on an answer to the problem. Now Portland biotech firm DesignMedix Inc. believes it has a cure for drug-resistant malaria parasites. The drug – DM1157 – is in human clinical trials at the Duke Clinical Research Institute in North Carolina. In 2006, Lynnor Stevenson (currently DesignMedix CEO) and Sandra Shotwell were consultants working with the Bill and Melinda Gates Malaria Vaccine Initiative. Among other things, they learned about various business models, one of which included mentoring entrepreneurs in the Portland area. Shotwell and Stevenson met David Peyton, a Portland State University chemistry professor who wanted to find a way to develop [...]